Dipeptidyl peptidase IV (DPP4), DPP8, DPP9 and FAP (fibroblast activation protein), the four proteases of the DPP4 gene family, have unique peptidase and extra-enzymatic activities that have been implicated in various diseases including cancers. We report here a novel role of DPP9 in regulating cell survival and proliferation through modulating molecular signaling cascades. Akt (protein kinase B) activation was significantly inhibited by human DPP9 overexpression in human hepatoma cells (HepG2 and Huh7) and human embryonic kidney cells (HEK 293T), whereas extracellular signal-regulated kinases (ERK1/2) activity was unaffected, revealing a pathway-specific effect. Interestingly, the inhibitory effect of DPP9 on Akt pathway activation was growth factor dependent. DPP9 overexpression caused apoptosis and significantly less EGF-mediated Akt activation in HepG2 cells. However, such inhibitory effect was not observed in cells stimulated with other growth factors, including connective tissue growth factor (CTGF), hepatic growth factor (HGF), insulin or platelet derived growth factor-BB (PDGF-BB). The effect of DPP9 on Akt did not occur when DPP9 enzyme activity was ablated by either mutagenesis or inhibition. The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a major downstream effector of Ras. We found that DPP9 and DPP8, but not DPP4 or FAP, associate with H-Ras, a key signal molecule of the epidermal growth factor receptor (EGFR) signaling pathway. These findings suggest an important signaling role of DPP9 in the regulation of survival and proliferation pathways.
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Introduction
The dipeptidyl peptidase IV (DPP4) gene family consists of four atypical serine proteases, including DPP4, fibroblast activation protein (FAP), DPP8 and DPP9. Upon dimerisation, this protein family mediates diverse biological processes by releasing the Nterminal dipeptide of substrates with proline at the penultimate position. DPP4 is known to have multiple roles, including T cell activation and proliferation, metabolic control and cancer cell biology (1-3), whereas FAP has been implicated in arthritis (4, 5) , cancers (6) and lung and liver fibrosis (7) (8) (9) . DPP8 and DPP9 are ubiquitously expressed in tissues (10, 11) .
We have previously reported that DPP8 and DPP9 are enriched in epithelial cells, lymphocytes and hepatocytes in vivo and various cancer cell lines, including Jurkat (human T cell lymphoma), Raji (human B cell Burkitt's lymphoma), Huh7 and HepG2 cells (human hepatocellular liver carcinoma cell lines) (10) . In vivo, DPP9 mRNA expression is significantly induced in testicular cancer (10) , whereas DPP8/9 enzyme activity is not significantly upregulated in gliomas compared to non-tumorous human brain (12) . The biological functions of DPP8 and DPP9 remain to be elucidated.
Over-expression of DPP9 in HEK293T cells results in impaired cell adhesion and migration (13) , suggesting a role of DPP9 in the regulation of cell growth and mobility.
Interestingly, a DPP8/DPP9 selective inhibitor, (2S,3R)-2-(2-amino-3-methyl-1-oxopentan-1-yl)-1,3-dihydro-2H-isoindole hydrochloride, attenuates lymphocyte proliferation (14, 15) .
Recently, the antigenic peptide RUI [34] [35] [36] [37] [38] [39] [40] [41] [42] has been identified as a natural DPP9 substrate, indicating a potential role of DPP9 in cytoplasmic peptide degradation for antigen presentation (16) .
Several lines of evidence suggest that DPP4 may be involved in cell signaling. DPP4 over-expression in prostate cancer cells blocks the basic fibroblast growth factor (bFGF) pathway (17) . In the Burkitt's B-cell lymphoma line DPP4 overexpression results in elevated p38 mitogen-activated protein kinases (MAPK; ERK1/2) phosphorylation (18) . Using the non-selective DPP inhibitor Diprotin A, Arscott et al demonstrated that DPP4 enzyme activity downregulates fetal calf serum (FCS) stimulated Akt phosphorylation in the neuroblastoma cell line, SK-N-AS (2). However, an important remaining question is whether DPP4 could function as a cytoplasmic signaling enzyme in addition to its extracellular dipeptidyl peptidase activity.
Epidermal growth factor receptor (EGFR) is a prototypical member of the ErbB family of tyrosine kinases that plays important roles in regulation of cell survival, growth, proliferation, and differentiation (19) . Upon ligand binding, dimerisation of EGFR triggers the activation of its receptor tyrosine kinase activity, resulting in the recruitment and phosphorylation of multiple intracellular substrates and the subsequent transduction of extracellular signals to the nucleus through an intracellular signaling network. EGFR upregulation has been implicated in the pathogenesis of a wide range of human cancers, including breast, brain, colon, lung, and prostate cancers (20) . As a result, a number of therapeutic strategies have been developed to target the EGFR signaling axis for the treatment of cancers. Gefitinib and Erlotinib, for instance, are selective EGFR tyrosine kinase inhibitors that have been approved by the US Food and Drug Administration (FDA) for the treatment of advanced non-small cell lung cancer, whereas antibodies Cetuximab and Panitumumab that block ligand binding, and thereby EGFR activation, have been approved for the treatment of metastatic colorectal cancer (21) .
One of the well established downstream signaling pathways of EGFR is the Ras pathway. Activation of EGFR upon ligand binding promotes recruitment of adaptor and signaling molecules that activate Ras. Two of the most important and commonly studied pathways downstream of the H-Ras signaling are the ERK1/2 and the phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B) pathways, by which the EGFR regulates various cellular functions, including cell survival, growth, migration and proliferation (22) .
We report here a novel role of DPP9 in attenuating the PI3K/Akt signaling in an EGF dependent manner, leading to induction of intrinsic apoptosis and suppression of cell proliferation. This is the first indication of the significance of DPP9 enzyme activity in cell signaling.
Materials and Methods
Materials. Antibodies are detailed in Table 1 . Other materials were from Sigma-Aldrich (St Louis, MO, USA) unless stated.
Generation of constructs.
The DPP9-V5-His and DPP8-V5-His constructs have been described (13) . The DPP9-V5-His Ser729Ala enzyme-inactive mutant (mutDPP9-V5-His) was generated by subcloning a 2.4 kb HindIII/ PmlI (Eco72I) fragment containing the S729A mutation from DPP9-ECFP S729A (13) into DPP9-V5-His/pcDNA3.1 (11) . The DPP8-V5-His Ser739Ala enzyme-inactive mutant (mutDPP8-V5-His) was generated by subcloning a 2.4 kb EcoRI/Xba fragment containing the S739A mutation from DPP8-ECFP S739A (13) into DPP8-V5-His/pcDNA3.1 (11) . Transformed, ampicillin-resistant plasmid DNA was purified and completely sequenced. Enzyme activity of the constructs was measured on 50 μg lysates of transfected cells using the fluorescent substrate H-Ala-Pro-AFC (Bachem, Bubendorf, Switzerland) as described (10) . Tris-Acetate SDS-PAGE (catalog number EA03755BOX, Invitrogen) followed by immunoblotting. Relative band intensities were quantitatively analysed using Image J and normalised against control proteins as indicated. Annexin V positive cells that were PI-negative were considered to be the apoptotic cells.
Other procedures have been described (24) . 
MTS proliferation assay.

Results
DPP9 over-expression induces intrinsic apoptosis in HepG2 cells.
We had previously demonstrated that overexpression of DPP9 induces spontaneous apoptosis in HEK293T cells in the absence of external stimuli, suggesting a role of DPP9 in regulating the intrinsic apoptotic pathway (13) . Therefore, we investigated whether DPP9 enzyme activity induces intrinsic apoptosis by measuring the extent of caspase 9 activation. Cleavage of caspase 9 has served as a hallmark of intrinsic apoptosis. The levels of such active forms of caspase 9 (18, 35 and 38 kDa) and caspase 3 (15 and 20 kDa) were significantly elevated in cells transfected with wtDPP9 compared to an enzyme negative Ser729AlaDPP9 mutant, which lacked DPP activity due to mutation of the catalytic serine (Fig. 1) . Natural bovine DPP9 has a gel mobility at approximately 100 kDa (26) . Endogenous DPP9 in HepG2 cells was detected by immunoblot as two bands, at approximately 95 kDa and 110 kDa, whereas the recombinant DPP9-V5-His had an electrophoretic mobility of about 97 kDa (Fig 1D, Fig 2A) . Fig. 1) downregulated the phosphorylation of Akt, whereas total Akt expression levels were not changed compared to vector control, indicating an inhibitory effect of DPP9 on Akt activation. By contrast, neither phosphorylated ERK1/2 nor total ERK1/2 were influenced by DPP9 overexpression, suggesting a specific effect of DPP9 on the Akt pathway. Endogenous DPP8 expression, which in some cell lines is detected at 160 kDa on SDS-PAGE ( Fig. 2A; data not shown), was unaffected by DPP9 overexpression (Fig. 2) , so DPP8 probably does not contribute to the observed Akt inhibition. response to EGF stimulation when DPP9-transfected (Fig. 4) . The time-course analysis shows that the DPP9-mediated inhibition was sustained over the period of Akt activation (5 to 30 min post-EGF stimulation), suggesting that DPP9-mediated inhibition affects the process rather than the kinetics of Akt activation.
The inhibitory effect of DPP9 on Akt depends on DPP9 enzymatic activity. Since DPP9 enzyme activity is required for induction of intrinsic apoptosis, we tested whether DPP9 enzyme activity is required for inhibition of Akt phosphorylation. Interestingly, the enzyme negative Ser729Ala mutDPP9 failed to attenuate Akt phosphorylation in both HepG2 and Huh7 cell lines (Fig. 5 A-D) , indicating that the inhibitory effect of DPP9 on Akt is dependent on its DPP activity and that it is not cell line specific. EGF stimulation did not alter the level of DPP9 enzyme activity ( Supplementary Fig. 2 ). Although highly homologous to DPP9, DPP8 enzyme activity did not affect Akt activation (Fig 5 E-F) .
Inhibition of DPP9 enzyme activity using an inhibitor of DPP8 and DPP9 provided further evidence that the DPP9-mediated downregulation of Akt phosphorylation was primarily due to DPP9 enzyme activity. (Fig 5 G-I) . In agreement with our previous report (13) , overexpression of wtDPP9 in HepG2 cells resulted in a significant increase in apoptosis. Notably, the wtDPP9-transfected cells exhibited more cell death than the mutant-transfected cells (Fig. 6A) (Supplementary Fig. 3 ).
Similarly, in the presence of EGF significantly greater percentages of apoptotic cells were observed in wtDPP9 (2% to 3%) compared to mutDPP9 (0.6% to 1.1%) transfected cells (Fig. 6A) . By contrast, EGF did not alter the extent of increased apoptosis conferred by DPP9 enzyme activity, suggesting a EGF-independent mechanism whereby DPP9 induces apoptosis. Serving as a control, the PI3K inhibitor (LY294002) treated cells showed significantly more apoptosis either with or without EGF stimulation (Fig. 6B, Supplementary   Fig. 4 ).
Akt signaling is known to regulate cell proliferation, therefore we examined whether inhibition of Akt signaling by DPP9 alters cell proliferation, determined by the MTS assay.
EGF promoted proliferation of HepG2 cells (Fig. 7) . Interestingly, wtDPP9 over-expressing 
cells showed about 50% less MTS activity at time 48 and 72 hours post-replating compared to mutDPP9-or vector-transfected cells in the presence of EGF, suggesting that DPP9 enzyme activity may be involved in attenuating EGF-mediated HepG2 cell proliferation. Notably, this effect was similar without EGF treatment, suggesting an anti-proliferative role of DPP9 enzyme activity independent of EGF signaling. Consistent with the DPP9 data, LY294002 treated cells showed a significant decrease in MTS activity compared to untreated cells, indicating that the PI3K/Akt pathway is important for proliferation of these cells (Fig. 7   C) . While DPP4 and FAP have been documented to cause cell cycle arrest (17, 27) and cell cycle arrest was anticipated from the proliferation data, we did not detect any influence of DPP9 on cell cycle in the conditions of our assay (Supplementary Fig. 3C ).
In vitro binding of DPP9 to H-Ras. One of the key regulators of Akt activation is HRas. We investigated the potential for interactions between H-Ras and DPP9 in the HeLa cell line, which was chosen due to high levels of endogenous H-Ras and DPP9 expression. The association of H-Ras and DPP9 was shown by co-IP of endogenous H-Ras and its ligands. HRas associated proteins that were pulled down by antibodies against H-Ras exhibited DPP activity measured by hydrolysis of the DPP substrate H-Ala-Pro-AFC (Table 2 ). This data is concordant with immunoblots of the immunocomplexes of H-Ras, which included DPP8 and DPP9, but not DPP4 or FAP (Fig. 8) . This probably reflects structural features: DPP8 and DPP9 are structurally similar (79% amino acid similarity and 61% amino acid identity), whereas DPP4 and FAP are highly homologous (52% amino acid identity), but only 27% identical to DPP8 and DPP9 (11) . DPP9 was detected as a strong 80 kDa and a weaker 130 kDa band, whereas DPP8 was seen at approximately 110 and 150 kDa with similar band intensities. The DPP4 dimer runs unexpectedly fast at about 150 kDa from a 110 kDa monomer (25, 28) , so DPP9 at 130 kDa and DPP8 at 150 kDa may be dimers while the faster bands are monomer and possibly fragments (10, 11) . 
Discussion
This is the first report of a protein ligand of DPP8 and DPP9 and of a role for DPP9 enzyme activity in cell signaling. We showed that DPP9 and its homolog DPP8 associate with the oncogene H-Ras. We also demonstrated a novel biological significance of DPP9 enzyme activity in EGF-mediated signaling and cellular function. Our data indicate important roles of DPP9 enzyme activity in mitogenic signaling, and thus of cell functions including apoptosis and proliferation that are inadequately regulated in most cancers. We showed that DPP9 enzyme activity attenuates PI3K/Akt, but not ERK1/2 pathway activation. Among the five growth factors examined, including CTGF, EGF, HGF, insulin and PDGF, EGF was the only growth factor that exhibited DPP9 mediated inhibition of Akt phosphorylation in HepG2 and Huh7 cells. Of interest for the pathogenesis of liver disease, we showed that DPP9 is downregulated in liver cirrhosis.
It has been reported that DPP4 enzyme activity suppresses FCS stimulated Akt phosphorylation in SK-N-AS cells (2) . In that study, introduction of the non-selective DPP inhibitor Diprotin A (the tripeptide Ile-Pro-Ile) to DPP4 transfected cells blocked the DPP4-mediated anti-phospho Akt effect (2) . As Diprotin A inhibits all peptidases of the DPP4 family, its effect on Akt activation might be due to inhibition of DPP8 and/or DPP9, rather than DPP4 per se. A DPP9 -selective inhibitor is not available so an inhibitor of both DPP8
and DPP9 was used to show involvement of DPP9 enzyme activity. Specificity for DPP9 was indicated in the current study by showing that EGF-stimulated Akt phosphorylation was unaffected in DPP8 overexpressing cells. Whether the effect of DPP4 on Akt is ligand specific has not been established. Differences in cellular localisation between DPP4 and DPP9 suggest that these two peptidases might attenuate Akt activation through distinct mechanisms. DPP4 is mainly expressed on the cell surface, whereas DPP9 expression is exclusively intracellular (11) . Nevertheless, a phosphorylated form of DPP4 has been reported in cytoplasm (29) . these data might alternatively suggest an EGF-independent mechanism that is yet to be characterised whereby DPP9 enzyme activity induces apoptosis. Consistent with PI3K/Akt pathway inhibition, we showed that DPP9 enzyme activity curtails proliferation and induces intrinsic apoptosis in HepG2 cells.
DPP9 may have a role in cancer cell development through influencing the PI3K/Akt signaling pathway. DPP9 mRNA levels are elevated in testicular tumours (10) , which have a deregulated increase in Akt activation (30) , and DPP9 is most readily detected in transformed cells (11) . Perhaps up-regulation of DPP9 in tumours serves as a mechanism to dampen the progression of cancer cell growth, proliferation and survival.
DPP9 is expressed in lymphocytes and epithelial cells, notably hepatocytes in vivo and hepatocarcinoma cell lines in vitro (10, 11) . DPP9 protein was down-regulated in ALD and PBC cirrhotic human livers compared to non-diseased controls. These diseases often progress to hepatocellular carcinoma. DPP9 is redox sensitive (31), so DPP9 enzyme activity might be further downregulated by the increased oxidation that occurs in damaged hepatocytes. This DPP9 down-regulation in cirrhosis occurs at a time of EGF signaling up-regulation (32) , and may contribute to increased Akt activation that has been detected in cirrhotic human livers (33) . Perhaps diminished DPP9 expression enhances growth factor signaling and/or lessens apoptosis, and thus contributes to increased hepatic cell proliferation in end-stage liver diseases, facilitating progression to hepatocellular carcinoma.
Redox regulation of DPP9 might be involved in modulating the PI3K/Akt pathway. We have shown that DPP9 enzyme activity is reversibly inactivated by oxidation (31) . An oxidative cellular environment created under oxidative stress or production of reactive oxygen species (ROS) during cellular metabolism, such as growth factor stimulation, inhibits the PI3K/Akt pathway through inactivation of PTEN, a PtdIns(3,4,5)P3 phosphatase that antagonises PI3K function (34) . As the enzyme activities of PTEN and DPP9 are both redox state dependent, the redox condition might be a molecular switch in PI3K/Akt pathway regulation.
Since DPP9 is a cytoplasmic protein, endosomal signaling of EGFR is a potential route for DPP9 to modulate Akt activation. Activation of H-Ras by EGF/EGFR within endosomes has been reported by several groups (35) (36) (37) 
endosomal EGFR/H-Ras complexes are formed by fusion of endosomes that contain EGFR with endosomes that contain H-Ras (35) . Endosomal EGFR signaling alone is sufficient to activate the major signaling pathways, including the Akt cascade that regulates cell proliferation and survival (38) . A preferential enrichment of H-Ras over K-Ras in endosomes can occur in A-431 cells (39) . Further investigation might determine whether DPP9 is recruited to the endosomal membrane in a complex with H-Ras upon EGFR activation, where DPP9 may exert its attenuating effect towards Akt phosphorylation, perhaps by cleaving one or more signaling or scaffolding molecules.
In summary, this study is the first indication of the significance of DPP9 enzyme activity in regulating cell behaviours, and the first data on a role of DPP9 in cell signaling. We demonstrated that DPP9 enzyme activity attenuates PI3K/Akt signaling in a growth factor specific manner, resulting in augmented apoptosis and suppressed cell proliferation. The effect of DPP9 on the PI3K/Akt pathway activation will need to be examined in vivo. It would be interesting to identify specific DPP9 substrates involved in attenuating the EGFR/PI3K/Akt pathway, which would provide a greater understanding of EGF action and Akt signaling.
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